Float Short %

14.37

Margin Of Safety %

Put/Call OI Ratio

0.27

EPS Next Q Diff

0.27

EPS Last/This Y

0.07

EPS This/Next Y

1.67

Price

7.38

Target Price

24.62

Analyst Recom

1.5

Performance Q

-24.95

Relative Volume

15.78

Beta

0.39

Ticker: URGN

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-05-08	URGN	10.66	0.28	0.03	7720
2025-05-09	URGN	10.36	0.28	0.48	7757
2025-05-12	URGN	11.14	0.29	0.52	8193
2025-05-13	URGN	10.12	0.28	0.76	8769
2025-05-14	URGN	9.85	0.30	3.56	9343
2025-05-15	URGN	9.85	0.44	0.77	10658
2025-05-16	URGN	7.3	0.53	0.11	13122
2025-05-19	URGN	7.96	0.26	0.46	24774
2025-05-20	URGN	7.54	0.30	0.71	29946
2025-05-21	URGN	4.17	0.34	0.35	37456
2025-05-22	URGN	4.07	0.34	0.10	52676
2025-05-23	URGN	4.19	0.28	0.26	60223
2025-05-27	URGN	3.96	0.29	0.17	68446
2025-05-28	URGN	4.05	0.29	0.15	69625
2025-05-29	URGN	3.97	0.30	0.08	68660
2025-05-30	URGN	4.24	0.29	0.06	70237
2025-06-02	URGN	4.84	0.24	0.60	84123
2025-06-03	URGN	5	0.25	0.17	86054
2025-06-04	URGN	4.91	0.26	3.08	86100
2025-06-05	URGN	5.13	0.28	0.18	87781
2025-06-06	URGN	7.38	0.27	0.26	90129
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-05-08	URGN	10.68	18.0	-	-2.88
2025-05-09	URGN	10.38	18.0	-	-2.88
2025-05-12	URGN	11.14	18.0	-	-2.88
2025-05-13	URGN	10.14	18.0	-	-2.88
2025-05-14	URGN	9.85	18.0	-	-2.88
2025-05-15	URGN	9.83	18.0	-	-2.88
2025-05-16	URGN	7.31	18.0	-	-2.88
2025-05-19	URGN	7.97	13.5	-	-2.88
2025-05-20	URGN	7.54	13.5	-	-2.88
2025-05-21	URGN	4.16	13.5	-	-2.88
2025-05-22	URGN	4.07	13.5	-	-2.88
2025-05-23	URGN	4.18	13.5	-	-2.88
2025-05-27	URGN	3.93	11.5	-	-2.89
2025-05-28	URGN	4.05	11.5	-	-2.89
2025-05-29	URGN	3.98	11.5	-	-2.89
2025-05-30	URGN	4.24	11.5	-	-2.89
2025-06-02	URGN	4.84	11.5	-	-2.89
2025-06-03	URGN	5.00	11.5	-	-2.89
2025-06-04	URGN	4.91	11.5	-	-2.89
2025-06-05	URGN	5.14	11.5	-	-2.89
2025-06-06	URGN	7.38	11.5	-	-2.89
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-05-08	URGN	-0.15	2.16	13.23
2025-05-09	URGN	-0.15	2.16	13.23
2025-05-12	URGN	-0.15	2.38	13.12
2025-05-13	URGN	-0.15	2.38	13.12
2025-05-14	URGN	-0.15	2.38	13.12
2025-05-15	URGN	-0.15	2.38	13.12
2025-05-16	URGN	-0.15	2.38	13.12
2025-05-19	URGN	-0.15	0.53	13.12
2025-05-20	URGN	-0.15	0.53	13.12
2025-05-21	URGN	-0.15	0.53	13.12
2025-05-22	URGN	-0.15	0.53	13.12
2025-05-23	URGN	-0.15	0.53	13.12
2025-05-27	URGN	-0.15	16.59	12.90
2025-05-28	URGN	-0.16	16.59	14.37
2025-05-29	URGN	-0.16	16.59	14.37
2025-05-30	URGN	-0.16	16.59	14.37
2025-06-02	URGN	-0.16	16.94	14.37
2025-06-03	URGN	-0.16	16.94	14.37
2025-06-04	URGN	-0.16	16.94	14.37
2025-06-05	URGN	-0.16	16.94	14.37
2025-06-06	URGN	-0.16	16.94	14.37
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.92

Avg. EPS Est. Current Quarter

-0.81

Avg. EPS Est. Next Quarter

-0.65

Insider Transactions

-0.16

Institutional Transactions

16.94

Beta

0.39

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

76.1

Max Drawdown 5-Year %

-86.8

Target Price

24.62

P/E

Forward P/E

PEG

P/S

3.7

P/B

P/Free Cash Flow

EPS

-3.18

Average EPS Est. Cur. Y

-2.89

EPS Next Y. (Est.)

-1.22

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-150.68

Relative Volume

15.78

Return on Equity vs Sector %

273.9

Return on Equity vs Industry %

291.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 234

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y